PLoS Pathogens (Jan 2025)

CD16 and CD57 expressing gamma delta T cells in acute HIV-1 infection are associated with the development of neutralization breadth.

  • Gina L Griffith,
  • Kawthar Machmach,
  • Ningbo Jian,
  • Dohoon Kim,
  • Margaret C Costanzo,
  • Matthew Creegan,
  • Isabella Swafford,
  • Gautam Kundu,
  • Lauren Yum,
  • Jessica S Bolton,
  • Lauren Smith,
  • Bonnie M Slike,
  • Elke S Bergmann-Leitner,
  • Rasmi Thomas,
  • Nelson L Michael,
  • Julie A Ake,
  • Leigh Anne Eller,
  • Merlin L Robb,
  • Samantha M Townsley,
  • Shelly J Krebs,
  • Dominic Paquin-Proulx,
  • RV217 Study Group

DOI
https://doi.org/10.1371/journal.ppat.1012916
Journal volume & issue
Vol. 21, no. 1
p. e1012916

Abstract

Read online

New HIV vaccine approaches are focused on eliciting broadly neutralizing antibodies. We characterized early gamma-delta (γδ) T cell responses starting from pre-acquisition and during acute HIV infection (AHI) in participants previously characterized for neutralization breadth development. We found significant differences in γδ T cell surface marker expression in participants that developed neutralization breadth compared to those that did not. Activation of γδ T cells occurred within the first weeks of HIV acquisition and associated with viral load. Expression of CD16 on Vδ1 T cells and CD57 on Vδ2 T cells were found to be significantly higher in broad neutralizers during AHI, and associated with the development of neutralization breadth years later. In addition, the levels of CD16 on Vδ1 T cells was associated with early production of founder virus Env-specific IgM. Thus, γδ T cells may promote development of neutralization breadth, which has implications for HIV vaccine strategies.